Allergic rhinoconjunctivitis (AR) is the most common IgE-mediated disease. A type2 immune response is involved in AR pathogenesis. Allergic inflammation is characterized by eosinophilic infiltrate and mediators release. AR treatment is usually based on medication prescription, including antihistamines and intranasal corticosteroids. However, medications may be prescribed for long periods and sometimes may be scarcely effective, thus aggressive strategy should be used. Therefore, complementary medicine is becoming attractive for patients at present. Nutraceuticals represent interesting therapeutic options in clinical practice. In this regard, a new compound has been designed containing Vitamin D3, Perilla extract, and quercetin.

Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach / Ciprandi, Giorgio; Leonardi, Salvatore; Zicari, Anna Maria; Angela Tosca, Maria; Marseglia, Gianluigi. - In: ACTA BIOMEDICA. - ISSN 2531-6745. - 91:1(2020), pp. 93-96. [10.23750/abm.v91i1.9274]

Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach

Anna Maria Zicari;
2020

Abstract

Allergic rhinoconjunctivitis (AR) is the most common IgE-mediated disease. A type2 immune response is involved in AR pathogenesis. Allergic inflammation is characterized by eosinophilic infiltrate and mediators release. AR treatment is usually based on medication prescription, including antihistamines and intranasal corticosteroids. However, medications may be prescribed for long periods and sometimes may be scarcely effective, thus aggressive strategy should be used. Therefore, complementary medicine is becoming attractive for patients at present. Nutraceuticals represent interesting therapeutic options in clinical practice. In this regard, a new compound has been designed containing Vitamin D3, Perilla extract, and quercetin.
2020
allergic rhinoconjunctivitis; inflammation; immune response; nutraceuticals
01 Pubblicazione su rivista::01a Articolo in rivista
Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach / Ciprandi, Giorgio; Leonardi, Salvatore; Zicari, Anna Maria; Angela Tosca, Maria; Marseglia, Gianluigi. - In: ACTA BIOMEDICA. - ISSN 2531-6745. - 91:1(2020), pp. 93-96. [10.23750/abm.v91i1.9274]
File allegati a questo prodotto
File Dimensione Formato  
Ciprandi_Allergic-rhinoconjunctivitis_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.26 MB
Formato Adobe PDF
1.26 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1475249
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact